The mutation frequencies of IDH1 and ATRX in gliomas with a low-risk score were remarkably higher than in gliomas with a high-risk score (IDH1, 92% vs. 31%; ATRX, 33% vs. 21%), while TTN and MUC16 had lower mutation frequencies (TTN, 8% vs. 21%; MUC16, 7% vs. 10%). This evidence concerns the gene ATRX and central nervous system cancer.